A proposed, evidence-based approach to the treatment of chronic Hepatitis B. J Clin Gastroenterol 2011 Mar;45(3):259-66
Date
09/22/2010Pubmed ID
20856136DOI
10.1097/MCG.0b013e3181f312f5Scopus ID
2-s2.0-79951809485 (requires institutional sign-in at Scopus site) 7 CitationsAbstract
Patients with chronic hepatitis B virus infection are at increased risk for the development of cirrhosis and hepatocellular carcinoma. Viral suppression with antiviral therapy has been shown to decrease the risk of these complications. Criteria for initiation of antiviral therapy have evolved over time to include serum alanine aminotransferase elevation, serum hepatitis B virus DNA elevations, and histologic assessment. Current societal guidelines and a treatment algorithm have been developed to guide decision-making as regards to antiviral therapy. More recent data has shown the importance of basal core/core promoter mutations, serum albumin, and platelet count in predicting complications of chronic hepatitis B. We present a new treatment strategy for determining the need for antiviral therapy in patients with chronic hepatitis B.
Author List
Han SH, Durazo FA, Saab S, Tong MJAuthor
Francisco A. Durazo MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Alanine TransaminaseAntiviral Agents
Carcinoma, Hepatocellular
DNA, Viral
Disease Progression
Evidence-Based Medicine
Hepatitis B virus
Hepatitis B, Chronic
Humans
Interferons
Liver Cirrhosis
Liver Neoplasms
Mutation
Nucleosides
